Zimmer Biomet at Goldman Sachs Conference: Strategic Growth and Challenges

At the Goldman Sachs Global Healthcare Conference, Zimmer Biomet (ZBH) expressed confidence in achieving its 2025 organic revenue growth target of 3% to 5%, driven by new product launches and the successful integration of Paragon 28, while acknowledging potential $60-80 million tariff headwinds. Q1 2025 organic constant currency revenue grew 2.3%-2.4% (closer to 4% adjusted for day rate), and Q2 is expected to outperform Q1, with stronger growth anticipated in the second half due to favorable comparisons and new product impacts. Management highlighted a focus on M&A for capital deployment, opportunistic stock buybacks, and a goal to reach a 5% weighted average market growth rate by 2027 through organic growth and acquisitions.

Analysis

Zimmer Biomet (ZBH) reiterated its confidence in achieving 3% to 5% organic revenue growth for 2025 during the Goldman Sachs 46th Annual Global Healthcare Conference, underpinned by new product launches and the successful integration of the Paragon 28 acquisition. The company reported Q1 2025 organic constant currency revenue growth of 2.3% to 2.4%, or closer to 4% when adjusted for day rate, and anticipates Q2 will outperform Q1, with a significant growth acceleration expected in the second half of 2025 due to favorable prior-year comparisons, the full impact of its "Magnificent Seven" new products, and specific international orders. Management detailed an estimated tariff impact of $60 million to $80 million for 2025, adopting a conservative stance that does not yet factor in potential benefits from the Nairobi protocol or the persistence of currently lower tariff rates, suggesting potential upside. The Paragon 28 integration is reportedly exceeding expectations with no talent loss or sales disruptions, enhancing cross-selling opportunities and validating ZBH's M&A playbook. Gross margins are projected to remain stable, supported by volume leverage from anticipated growth and manufacturing repositioning to lower-cost countries, despite ongoing pricing pressures. The company highlighted strong Q1 US hip sales, with continued momentum into Q2, and aims to significantly increase US robotics penetration from 20-23% and cementless knees from near 30% towards 60% within three years. Capital deployment will prioritize M&A, with stock buybacks considered opportunistically, aiming to reduce the leverage ratio to the low 3s. ZBH also noted consistent earnings growth of 5% to 9% over the last four years, excluding COVID impacts, and is targeting a 5% weighted average market growth rate by 2027 through a combination of organic growth and further M&A.

Key Decisions for Investors

• Investors should monitor Zimmer Biomet's execution on its new product launches, particularly the 'Magnificent Seven' and Persona Osteo Tie with ROSA robotics, as their second-half 2025 ramp-up is critical to achieving the reaffirmed 3-5% organic revenue growth guidance and demonstrating sustained market share gains.
• Consider the potential for earnings upside relative to current guidance if the estimated $60-80 million tariff impact for 2025 proves overly conservative, either through the applicability of the Nairobi Protocol or continued lower tariff rates, which management has not yet factored into projections.
• Evaluate the company's strategic M&A focus, exemplified by the successful Paragon 28 integration, as a key driver for achieving its target of a 5% weighted average market growth rate by 2027 and enhancing its position in higher-growth segments, while also noting the opportunistic approach to stock buybacks contingent on M&A pipeline and market conditions.
• Assess the company's ability to maintain stable gross margins through volume leverage, manufacturing efficiencies, and portfolio rationalization, particularly in the context of potential foreign exchange headwinds and ongoing pricing pressures in the medtech industry.
• Note management's confidence in delivering mid-single-digit top-line growth and 5-9% underlying earnings growth, supported by a strengthened US commercial team and strategic reallocation of investments, while being mindful of the back-half weighting of 2025 growth.